Management of Hypercholesterolemia in Young Adults

Diagnostic Considerations

The American Academy of Pediatrics recommends that a 21-year-old female with LDL cholesterol of 212 mg/dL be considered for heterozygous familial hypercholesterolemia (HeFH) diagnosis, with key clinical features including family history of premature cardiovascular disease and physical examination for tendon xanthomas 1
The American College of Cardiology suggests evaluating for secondary causes of hypercholesterolemia, including hypothyroidism, nephrotic syndrome, obstructive liver disease, medications, diabetes mellitus, and obesity 2, 3

The American Academy of Pediatrics classifies a 21-year-old female with isolated hypercholesterolemia as Tier II (moderate risk), but notes that LDL-C >190 mg/dL warrants consideration for pharmacotherapy regardless of other risk factors 1, 3, 4
The American College of Cardiology recommends evaluating for additional risk factors, including blood pressure, BMI, fasting glucose, family history of premature CVD, smoking status, and physical inactivity 1, 3

The American College of Cardiology recommends initiating intensive therapeutic lifestyle changes, including dietary modifications (saturated fat <7% of total energy intake, cholesterol intake <200 mg/day) and physical activity (minimum 30 minutes moderate-intensity activity most days of the week) 3, 1
The American College of Cardiology suggests that LDL-C ≥190 mg/dL warrants pharmacotherapy regardless of other risk factors or CVD presence, with a recommended approach of initiating moderate-intensity statin therapy (e.g., atorvastatin 10-20 mg or rosuvastatin 5-10 mg daily) 3, 4, 5
The American College of Cardiology recommends targeting an LDL-C goal of <100 mg/dL, with consideration of high-intensity statin if suspected FH or multiple risk factors are present 3, 1, 4

The American College of Cardiology recommends reassessing lipid panel 4-12 weeks after initiating statin, with monitoring of liver enzymes and assessment for myopathy symptoms as clinically indicated 5, 4
The American College of Cardiology suggests intensifying statin dose or considering addition of ezetimibe 10 mg daily if LDL-C goal is not achieved on statin monotherapy 5